{
    "id": "18f76802-50d1-48a3-8d20-4af21bf1b188",
    "indications": "afinitor kinase inhibitor indicated treatment : postmenopausal women advanced hormone receptor-positive , her2-negative breast cancer combination exemestane failure treatment letrozole anastrozole . ( 1.1 ) adults progressive neuroendocrine tumors pancreatic origin ( pnet ) adults progressive , well-differentiated , non-functional neuroendocrine tumors ( net ) gastrointestinal ( gi ) lung origin unresectable , locally advanced metastatic . limitations : afinitor indicated treatment patients functional carcinoid tumors . ( 1.2 ) adults advanced renal cell carcinoma ( rcc ) failure treatment sunitinib sorafenib . ( 1.3 ) adults renal angiomyolipoma tuberous sclerosis complex ( tsc ) , requiring immediate surgery . ( 1.4 ) afinitor afinitor disperz kinase inhibitors indicated treatment adult pediatric patients aged 1 year older tsc subependymal giant cell astrocytoma ( sega ) requires therapeutic intervention curatively resected . ( 1.5 ) afinitor disperz kinase inhibitor indicated adjunctive treatment adult pediatric patients aged 2 years older tsc-associated partial-onset seizures . ( 1.6 )",
    "contraindications": "combine afinitor afinitor disperz achieve total daily dose . ( 2.1 ) modify dose patients hepatic impairment patients taking drugs inhibit induce p-glycoprotein ( p-gp ) cyp3a4 . ( 2.1 ) breast cancer : 10 mg orally daily . ( 2.2 ) net : 10 mg orally daily . ( 2.3 ) rcc : 10 mg orally daily . ( 2.4 ) tsc-associated renal angiomyolipoma : 10 mg orally daily . ( 2.5 ) tsc-associated sega : 4.5 mg/m 2 orally daily ; adjust dose attain trough concentrations 5-15 ng/ml . ( 2.6 , 2.8 ) tsc-associated partial-onset seizures : 5 mg/m 2 orally daily ; adjust dose attain trough concentrations 5-15 ng/ml . ( 2.7 , 2.8 )",
    "warningsAndPrecautions": "afinitor 2.5 mg tablets : white slightly yellow , elongated tablets bevelled edge engraved “ lcl ” one side “ nvr ” ; available : blisters 28 tablets………………………………………………………………………………ndc 0078-0594-51 carton contains 4 blister cards 7 tablets 5 mg tablets : white slightly yellow , elongated tablets bevelled edge engraved “ 5 ” one side “ nvr ” ; available : blisters 28 tablets………………………………………………………………………………ndc 0078-0566-51 carton contains 4 blister cards 7 tablets 7.5 mg tablets : white slightly yellow , elongated tablets bevelled edge engraved “ 7p5 ” one side “ nvr ” ; available : blisters 28 tablets………………………………………………………………………………ndc 0078-0620-51 carton contains 4 blister cards 7 tablets 10 mg tablets : white slightly yellow , elongated tablets bevelled edge engraved “ uhe ” one side “ nvr ” ; available : blisters 28 tablets………………………………………………………………………………ndc 0078-0567-51 carton contains 4 blister cards 7 tablets afinitor disperz 2 mg tablets oral suspension : white slightly yellowish , round , flat tablets bevelled edge engraved “ d2 ” one side “ nvr ” ; available : blisters 28 tablets………………………………………………………………………………ndc 0078-0626-51 carton contains 4 blister cards 7 tablets 3 mg tablets oral suspension : white slightly yellowish , round , flat tablets bevelled edge engraved “ d3 ” one side “ nvr ” ; available : blisters 28 tablets………………………………………………………………………………ndc 0078-0627-51 carton contains 4 blister cards 7 tablets 5 mg tablets oral suspension : white slightly yellowish , round , flat tablets bevelled edge engraved “ d5 ” one side “ nvr ” ; available : blisters 28 tablets………………………………………………………………………………ndc 0078-0628-51 carton contains 4 blister cards 7 tablets store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) . usp controlled room temperature . store original container , protect light moisture . follow special handling disposal procedures anti-cancer pharmaceuticals.1",
    "adverseReactions": "afinitor/afinitor disperz contraindicated patients clinically significant hypersensitivity everolimus rapamycin derivatives [ ( 5.3 ) ] .",
    "ingredients": [
        {
            "name": "EVEROLIMUS",
            "code": "9HW64Q8G6G"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        }
    ],
    "organization": "Novartis Pharmaceuticals Corporation",
    "name": "Afinitor",
    "effectiveTime": "20250514",
    "indications_original": "AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) AFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. ( 1.6 )",
    "contraindications_original": "Do not combine AFINITOR and AFINITOR DISPERZ to achieve the total daily dose. ( 2.1 ) Modify the dose for patients with hepatic impairment or for patients taking drugs that inhibit or induce P-glycoprotein (P-gp) and CYP3A4. ( 2.1 ) Breast Cancer: 10 mg orally once daily. ( 2.2 ) NET: 10 mg orally once daily. ( 2.3 ) RCC: 10 mg orally once daily. ( 2.4 ) TSC-Associated Renal Angiomyolipoma: 10 mg orally once daily. ( 2.5 ) TSC-Associated SEGA: 4.5 mg/m 2 orally once daily; adjust dose to attain trough concentrations of 5-15 ng/mL. ( 2.6 , 2.8 ) TSC-Associated Partial-Onset Seizures: 5 mg/m 2 orally once daily; adjust dose to attain trough concentrations of 5-15 ng/mL. ( 2.7 , 2.8 )",
    "warningsAndPrecautions_original": "AFINITOR\n                  \n                  2.5 mg tablets: White to slightly yellow, elongated tablets with a bevelled edge and engraved with “LCL” on one side and “NVR” on the other; available in:\n                  Blisters of 28 tablets………………………………………………………………………………NDC 0078-0594-51\n                  Each carton contains 4 blister cards of 7 tablets each\n                  5 mg tablets: White to slightly yellow, elongated tablets with a bevelled edge and engraved with “5” on one side and “NVR” on the other; available in:\n                  Blisters of 28 tablets………………………………………………………………………………NDC 0078-0566-51\n                  Each carton contains 4 blister cards of 7 tablets each\n                  7.5 mg tablets: White to slightly yellow, elongated tablets with a bevelled edge and engraved with “7P5” on one side and “NVR” on the other; available in:\n                  Blisters of 28 tablets………………………………………………………………………………NDC 0078-0620-51\n                  Each carton contains 4 blister cards of 7 tablets each\n                  10 mg tablets: White to slightly yellow, elongated tablets with a bevelled edge and engraved with “UHE” on one side and “NVR” on the other; available in:\n                  Blisters of 28 tablets………………………………………………………………………………NDC 0078-0567-51\n                  Each carton contains 4 blister cards of 7 tablets each\n                  \n                     AFINITOR DISPERZ\n                  \n                  2 mg tablets for oral suspension: White to slightly yellowish, round, flat tablets with a bevelled edge and engraved with “D2” on one side and “NVR” on the other; available in: \n                  Blisters of 28 tablets………………………………………………………………………………NDC 0078-0626-51\n                  Each carton contains 4 blister cards of 7 tablets each\n                  3 mg tablets for oral suspension: White to slightly yellowish, round, flat tablets with a bevelled edge and engraved with “D3” on one side and “NVR” on the other; available in: \n                  Blisters of 28 tablets………………………………………………………………………………NDC 0078-0627-51\n                  Each carton contains 4 blister cards of 7 tablets each\n                  5 mg tablets for oral suspension: White to slightly yellowish, round, flat tablets with a bevelled edge and engraved with “D5” on one side and “NVR” on the other; available in: \n                  Blisters of 28 tablets………………………………………………………………………………NDC 0078-0628-51\n                  Each carton contains 4 blister cards of 7 tablets each\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). See USP Controlled Room Temperature.\n                  Store in the original container, protect from light and moisture.\n\t\t\t\t\t\t\n                  Follow special handling and disposal procedures for anti-cancer pharmaceuticals.1",
    "adverseReactions_original": "AFINITOR/AFINITOR DISPERZ is contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives [see Warnings and Precautions (5.3)]."
}